[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai University of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":354},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,70,96,119,146,172,199,226,251,279,309,329],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100639258","a-study-of-acupuncture-for-treating-asthma-100639258",false,"NCT07611955","A Study of Acupuncture for Treating Asthma","The Effects of Acupuncture on Patients With Chronic Asthma: a Multicenter, Randomized, Three-arm, Sham-controlled Superiority Trial","Inclusion Criteria:\n\n* Meet the diagnostic criteria for asthma, and be in the chronic persistent phase with mild to moderate disease severity, referring to the grading criteria of the Guidelines for the Prevention and Treatment of Asthma (2024 Edition).\n* Aged 18 to 70 years, regardless of gender.\n* Asthma Control Test (ACT) score≤19 points (poorly controlled or very poorly controlled asthma).\n* Maintain a stable asthma treatment regimen for at least 4 weeks before enrollment.\n* Clear thinking and consciousness, coherent responses, able to understand the items of various scales and complete the assessment.\n* Volunteer to participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n* Complicated with severe mental illnesses (such as uncontrolled schizophrenia, acute phase of bipolar disorder, etc.) or moderate to severe cognitive impairment (such as dementia), resulting in inability to understand the research process or cooperate with efficacy evaluation.\n* A history of substance\u002Falcohol dependence within the past 12 months.\n* Complicated with other physical diseases that may cause depressive symptoms (such as hypothyroidism, chronic pain syndrome, malignant tumors, rheumatoid arthritis, etc.).\n* Received antidepressant drug treatment within the past 6 months.\n* Suffering from other respiratory diseases, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, etc.\n* Complicated with other cancers or relatively severe chronic diseases of the heart, liver, kidneys, etc.\n* Received acupuncture treatment within the past 3 months.\n* Pregnant or lactating women.","ALL","18 Years","70 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"NA","Asthma is a common chronic respiratory disease with a low clinical control rate, highlighting the need for novel therapeutic strategies. Recurrent asthma attacks emotional symptoms, such as anxiety and depression, etc. On the contrary, symptoms such as anxiety and depression worsen asthma control. Acupuncture is commonly applied as an effective traditional Chinese medical therapy for asthma. Acupoints GV14, BL13 and BL12 are adopted for the intervention of asthma. GV20 and GV29 are selected to improve emotional symptoms including depression. Nevertheless, standardized therapeutic regimens of acupuncture for asthma and its concomitant emotional symptoms are still lacking. 180 patients with mild to moderate asthma will be recruited in this multicenter randomized controlled trial, randomly assigned to the true acupuncture group, sham acupuncture group and usual care group. The primary outcome is the score of the Asthma Control Test (ACT). Secondary outcomes include the Hospital Anxiety and Depression Scale (HADS), Asthma Quality of Life Questionnaire (AQLQ), pulmonary function, and fractional exhaled nitric oxide (FeNO). The superiority of combined acupuncture therapy in improving asthma control, relieving negative emotions, and enhancing quality of life is to be verified in this study, with high quality evidence for acupuncture treatment of asthma thereby to be provided.",[27,28,29],"Asthma Chronic","Asthma (Diagnosis)","Asthma","NOT_YET_RECRUITING","2026-05-28",{"date":33,"type":34},"2026-06-01","ACTUAL",{"date":36,"type":21},"2026-05-21",{"date":38,"type":21},"2028-09",{"name":40,"class":41},"Shanghai University of Traditional Chinese Medicine","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100503373","clinical-study-on-the-prevention-of-driver-gene-negative-ib-iiib-lung-cancer-recurrence-and-metastasis-by-staged-chinese-herbal-medicine-combined-with-chemotherapy-and-immune-checkpoint-inhibitors-100503373","NCT05834413","Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n1. Patients who underwent complete surgical resection (R0) with postoperative pathology confirmed as stage Ib to IIIb non-small cell lung cancer.\n2. Patients whose tissue or blood specimens tested negative for driver genes.\n3. Patients who received their first chemotherapy within 8 weeks postoperatively.\n4. Age ≥ 18 years ≤ 74 years, regardless of gender.\n5. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2 points.\n6. absolute neutrophil value \\>1.5×109 \u002FL, platelet count \\>80×109 \u002FL, hemoglobin \\>90mg\u002FdL; no abnormal liver and kidney function test results.\n7. Understand and agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Having unresectable or metastatic disease, pathology reports without a clear pathological diagnosis, showing the presence of residual lesions at the microscopic surgical margins, and surgical residual lesions.\n2. Any medical condition with a life expectancy of less than 5 years, except for risk of recurrent lung cancer.\n3. Current malignant disease or history of malignant disease (except resected NSCLC), combined with serious diseases of the heart, liver, kidney and hematopoietic system, diagnosed and\u002For requiring treatment within the past three years.\n4. With a history of psychiatric disorders that are not easily controlled.\n5. Patients who are pregnant or lactating.\n6. Patients who are allergic to therapeutic drugs.","74 Years",{"count":50,"type":21},367,[24],"This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative adjuvant therapy: (i) chemotherapy phase immunotherapy phase. In this study, 367 patients (183 in the control group and 184 in the trial group) will be observed over 4 years, and the quality of life, toxic effects and safety of this therapy will be investigated. This study will provide evidence-based evidence for the establishment and optimization of a new model of postoperative staged TCM with adjuvant chemo-immunotherapy for lung cancer.",[54],"Lung Cancer",[56,57,58,59],"non-small cell lung cancer","traditional Chinese medicine","postoperative adjuvant therapy","immune checkpoint inhibitors","RECRUITING","2026-05-08",{"date":63,"type":34},"2026-05-13",{"date":65,"type":34},"2023-05-01",{"date":67,"type":21},"2027-06-30",{"name":40,"class":41},1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":69},"100586909","tcm-daoyin-for-anxietydepression-psychological-effects-and-biological-mechanisms-100586909","NCT06921512","TCM Daoyin for Anxiety\u002FDepression: Psychological Effects and Biological Mechanisms","TCM Daoyin for Anxiety and Depression Symptoms: Psychological Effects and Biological Mechanisms","Inclusion Criteria:\n\n* Primary symptoms of anxiety and depression, with a Hamilton Anxiety Rating Scale (HAMA-14) score between 14 and 29 and a Hamilton Depression Rating Scale (HAMD-17) score between 7 and 14.\n* No prior use of psychotropic medication, or at least six months since discontinuation.\n* Aged 18 to 65 years (male or female).\n* Clear consciousness and normal cognitive function, with the ability to communicate effectively, read, express thoughts, and engage in daily activities independently.\n* Willing and able to comply with blood and stool sample collection.\n* Voluntary participation, with signed informed consent provided before enrollment.\n\nExclusion Criteria:\n\n* Diagnosed anxiety disorder or depressive disorder based on ICD-10 criteria.\n* Bipolar disorder, psychotic disorders (e.g., schizophrenia), or organic mental disorders (e.g., Alzheimer's disease).\n* History of alcohol or substance use disorder within the past year, current psychiatric medication use, or high suicide risk.\n* Severe or unstable medical conditions, including immune or endocrine disorders or other serious illnesses.\n* Physical or psychological limitations preventing participation in the TCM Daoyin intervention.\n* Pregnant or breastfeeding women.","65 Years",{"count":79,"type":21},20,[24],"This 12-week single-arm clinical trial investigates the effects of Traditional Chinese Medicine (TCM) Daoyin exercise on anxiety and depression symptoms in 20 participants, followed by a 12-week observational follow-up period.\n\nThe primary outcome is the change in Hamilton Anxiety Rating Scale (HAMA-14) and Hamilton Depression Rating Scale (HAMD-17) scores at 12 weeks. A secondary outcome will assess these scores at 24 weeks to evaluate sustained effects. Additional secondary outcomes include the Depression, Anxiety, and Stress Scale (DASS-21) and Pittsburgh Sleep Quality Index (PSQI) to further assess changes in mood and sleep quality at the same time points.\n\nExploratory analyses will examine inflammatory markers, immune cell subsets, serum metabolomics, and gut microbiota at baseline, 12 weeks, and 24 weeks to identify potential biological correlates. During the follow-up period, participants will record their actual exercise engagement, allowing investigators to explore long-term associations. Findings may provide insights for future mechanistic studies on TCM's role in mental health.",[83,84],"Anxiety Symptom","Depression Symptom",[86,87],"Anxiety","Depression","2026-04-23",{"date":90,"type":34},"2026-04-29",{"date":92,"type":34},"2025-04-10",{"date":94,"type":21},"2027-09-30",{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":69},"100484537","baduanjin-training-for-depression-and-anxiety-patients-100484537","NCT05589337","Baduanjin Training for Depression and Anxiety Patients","Effects of Baduanjin Breathing Training for Depression and Anxiety Patients: a Prospective Randomized Study","Inclusion Criteria:\n\n* Subject with depression or anxiety symptom diagnosed by ICD-10.\n* Depression 7≤HAMD-17≤29，anxiety 7≤HAMA-14≤29.\n* Subject has a clear mind and the ability to read, to talk and to communicate.\n* Subject agrees to participate in this study and sign to the informed consent.\n\nExclusion Criteria:\n\n* Subject with bipolar disorder, psychotic disorder, organic mental disorder and cognitive disorder.\n* Subject with alcohol abuse, substance dependence and suicidal behavior in past-year.\n* Subject has severe somatic disease.\n* Subject is pregnant or lactating women.",{"count":104,"type":21},120,[24],"In recent years, the number of people with symptoms of depression or anxiety are on the rise. The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung functions.",[108,109],"Depression Symptoms","Anxiety Symptoms",[111,87,86,112],"Baduanjin","Randomized controlled trial",{"date":90,"type":34},{"date":115,"type":34},"2021-07-01",{"date":117,"type":21},"2027-07-30",{"name":40,"class":41},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100618447","development-and-application-of-a-parenting-anxiety-intervention-program-for-young-and-middle-aged-female-breast-cancer-patients-100618447","NCT07331740","Development and Application of a Parenting Anxiety Intervention Program for Young and Middle-Aged Female Breast Cancer Patients","Parenting Concerns of Young and Middle-aged Women With Breast Cancer: A Study Protocol for a Feasibility Trial","Inclusion Criteria:\n\n* Clear breast cancer patients confirmed by histopathology who have received surgical treatment\n* Aged 18 to 59 and currently raising at least one minor child under the age of 18\n* Clinical stage I - IV\n* Be aware of the condition, provide informed consent and voluntarily participate in this study\n* The patient can cooperate with the research independently and has normal reading, comprehension, thinking and judgment abilities\n\nExclusion Criteria:\n\n* Concurrent with other cancers\n* Engaged in psychology work, or having received psychological intervention guidance within the past six months\n* Participate in other nursing intervention studies simultaneously","FEMALE","59 Years",{"count":79,"type":21},[24],"This feasibility study aims to develop and test an intervention program for young and middle-aged female breast cancer patients who experience parenting concerns. Eligible participants will receive the tailored support program (including psychological counseling and parenting guidance). The study will assess whether the program is acceptable, feasible, and potentially helpful in reducing parenting concerns among this group.We plan to enroll 20 participants from Shanghai Zhoupu Hospital between March 2026 and October 2026.",[132,133],"Breast Cancer","Parenting Anxiety",[135,136,137,133],"Young and middle-aged female breast cancer patients","Intervention program","Feasibility trial","2026-01-09",{"date":140,"type":34},"2026-01-12",{"date":142,"type":21},"2026-03-01",{"date":144,"type":21},"2026-12-01",{"name":40,"class":41},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":153,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":69},"100619252","phase-2-a-study-on-the-treatment-of-patients-with-acute-lung-injury-caused-by-sepsis-through-microbiota-transplantation-100619252","NCT07342205","A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation","A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Clear or suspected infection + SOFA score ≥ 2 points, and PaO₂\u002FFiO₂ ≤ 300 mmHg;\n* Capable of taking in nutrients (able to eat independently or receive enteral nutrition);\n* Voluntarily participate in this trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Indications for exclusion from FMT (Fecal Microbiota Transplantation) include massive gastrointestinal bleeding, intestinal obstruction, organic intestinal disorders, and severe damage to intestinal mucosa;\n* Individuals with severe immune deficiencies, such as those with AIDS, leukemia, and those using immunosuppressive drugs;\n* Pregnant women and lactating women;\n* Those who cannot undergo nasal-intestinal catheterization or other transplantation methods;\n* Patients who cannot cooperate to complete the study; Other situations where the researchers determine that a patient is not suitable for participating in the clinical trial.",true,{"count":155,"type":21},60,[157,158],"PHASE2","PHASE3","Sepsis is a systemic inflammatory response syndrome triggered by infection, and it is a common critical illness in clinical practice, often leading to multiple organ dysfunction. Among these, acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are among the most severe complications. The mortality rate of sepsis-related lung injury is extremely high, reaching 30% - 50%. The existing treatment methods are unable to effectively reduce the high mortality rate of sepsis-related lung injury, and there are no specific treatment measures targeting lung injury itself. Dysbiosis of the intestinal flora plays an important role in the occurrence and development of sepsis-related lung injury. Fecal microbiota transplantation (FMT), as an effective means of regulating the intestinal flora, has shown certain therapeutic potential in some clinical studies. However, current research on FMT for treating sepsis-related lung injury is still in its infancy, and its mechanism is not yet fully clear. The clinical efficacy and safety also lack high-quality evidence support. Therefore, conducting this project's research will provide theoretical basis for targeted microecological treatment of sepsis-related lung injury; establishing a new strategy of combined microbiota transplantation technology for treating patients with sepsis ALI, and providing new ideas and methods for clinical treatment.",[161,162,163],"Acute Respiratory Distress Syndrome (ARDS)","Acute Lung Injury(ALI)","Sepsis Related Acute Lung Injury\u002FAcute Respiratory Distress Syndrome","2026-01-07",{"date":166,"type":34},"2026-01-15",{"date":168,"type":34},"2025-12-10",{"date":170,"type":21},"2027-06",{"name":40,"class":41},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100615694","phase-2-tcm-as-an-adjuvant-treatment-in-mycobacterium-abscessus-pulmonary-disease-100615694","NCT07295938","TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease","A Study to Assess the Traditional Chinese Medicine as Adjunctive Therapy to Improve Cure Rates During the Continuation Phase in Mycobacterium Abscessus Pulmonary Disease","Inclusion Criteria:\n\n* Patient diagnosed with Mycobacterium abscessus pulmonary disease;\n* Patients have completed the initial phase of treatment as recommended by the guidelines;\n* Patients who have given written informed consent\n* One week prior to enrollment, organ function levels must meet the following criteria: a. Hemoglobin ≥60g\u002FL; b. Neutrophil count ≥0.5×10\\^9\u002FL; c. Platelet count ≥60×10\\^9\u002FL; d. Serum total bilirubin ≤3 times the upper limit of normal; e. Aspartate aminotransferase ≤3 times the upper limit of normal; f. Alanine aminotransferase ≤3 times the upper limit of normal; g. Creatinine level below 2 times the upper limit of normal or creatinine clearance ≥60mL\u002Fmin; h. Urea nitrogen ≤200mg\u002FL; i. Urinary protein \\\u003C++, with ≥500mg total protein in 24-hour urine if protein is present; j. Blood glucose: within normal range and\u002For stable blood glucose control in diabetic patients; k. Cardiac function: no history of myocardial infarction within 6 months; no unstable angina; no severe arrhythmia.\n\nExclusion Criteria:\n\n* Patients with a drug allergy to the investigational medication;\n* Patients infected with two or more non-tuberculous mycobacteria, or those with active pulmonary tuberculosis;\n* Patients with a prior history of pulmonary parenchymal organ transplantation;\n* Patients with severe conditions such as congenital or acquired immunodeficiency disorders, active malignant tumors (primary or metastatic), or any malignancies requiring chemotherapy or radiotherapy during screening or study;\n* Patients undergoing dialysis;\n* Patients with radiation pneumonitis requiring corticosteroid or immunoglobulin pulse therapy, or clinically proven active interstitial lung disease, uncontrolled massive pleural effusion, or pericardial effusion;\n* Unstable systemic comorbidities (hypertensive crisis, unstable angina, congestive heart failure, myocardial infarction within the past 6 months, severe psychiatric disorders requiring medication, severe hepatic or renal dysfunction, neuropsychiatric conditions such as Alzheimer's disease);\n* Patients with intestinal dysfunction or malabsorption syndrome;\n* Pregnant or breastfeeding women;\n* Patients receiving other investigational drugs within 4 weeks prior to first exposure to the study drug;\n* Concurrent enrollment in another clinical trial, except for observational (non-interventional) studies or follow-up visits in interventional trials;\n* Physical examinations or clinical tests that the investigator deems potentially interfering with results or increasing treatment-related complications.","75 Years",{"count":181,"type":21},352,[157],"Chinese herbs can facilitate sputum culture conversion, promote lesion absorption, and enhance clinical symptoms and quality of life for patients with Mycobacterium abscessus pulmonary disease (MAB-PD). The investigators aimed to evaluate the efficacy of Chinese herbs as adjunct therapy to improve cure rates or reduce recurrence rates during the continuation phase of MAB-PD treatment.",[185],"Mycobacterium Abscessus Pulmonary Disease",[187,188,189],"Mycobacterium abscessus Pulmonary Disease","Continuation Phase","TCM","2025-12-19",{"date":192,"type":34},"2025-12-22",{"date":194,"type":34},"2025-09-08",{"date":196,"type":21},"2028-11",{"name":40,"class":41},8,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":17,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100598250","electroacupuncture-in-the-treatment-of-patients-undergoing-transperineal-prostate-biopsy-under-local-anesthesia-100598250","NCT07069049","Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia","Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia: a Randomized, Single-blind, Sham-electroacupuncture Parallel Control, Multi-center Clinical Trial","EATPULA","Inclusion Criteria:\n\n\\- (1) To voluntarily participate in the study, I or his legal representative signed a written informed consent.\n\n(2) 18-80 years old (including 18 and 80 years old), male. (3) in accordance with the indication of prostate biopsy.\n\nExclusion Criteria:\n\n* (1) in the stage of acute genitourinary infection or fever. (2) patients with chronic pain (such as bone metastasis of prostate cancer, knee osteoarthritis, scapulohumeral periarthritis, etc.) or acute pain (tonsillitis, acute lumbar sprain, etc.) before surgery.\n\n  (3) Continuous use of anti-anxiety or analgesic drugs (use of anti-anxiety drugs or analgesics for more than 1 week in the past 3 months).\n\n  (4) in the decompensated stage of cardiac insufficiency; A disease with a tendency to bleed heavily.\n\n  (5) severe immunosuppression. (6) hypertension, diabetes and other complications were poorly controlled or unstable.\n\n  (7) complicated with severe internal or external hemorrhoids, perianal or rectal lesions, and anal stenosis.\n\n  (8) perineal skin ulceration, infection, and abnormal skin sensation. (9) patients with serious psychological diseases or uncooperative puncture. (10) allergy to narcotic drugs and fear of acupuncture operators. (11) Participants who participated in other clinical trials within 3 months before enrollment.\n\n  (12) other conditions considered by the investigator to be inappropriate to participate in the trial.","MALE","80 Years",{"count":210,"type":21},190,[24],"Prostate biopsy is the gold standard for the diagnosis of prostate cancer, and transperineal puncture is a common approach. It has the advantages of no bowel preparation and relative safety. At present, transperineal puncture is often performed under local anesthesia, but there are still clinical problems such as pain and anxiety for patients. Electroacupuncture is often used as an auxiliary means of local anesthesia in China, which has the advantages of analgesia and anti-anxiety. This study was conducted to evaluate the efficacy and safety of electroacupuncture combined with local anesthesia in transperineal needle biopsy.",[214],"Prostate Cancer",[216,217,214],"electroacupuncture","Prostate Needle biopsy","2025-12-02",{"date":220,"type":34},"2025-12-09",{"date":222,"type":21},"2025-12-28",{"date":224,"type":21},"2026-09-28",{"name":40,"class":41},{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":207,"minAge":17,"maxAge":208,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100611804","electroacupuncture-for-improving-urinary-incontinence-after-radical-prostatectomy-100611804","NCT07245342","Electroacupuncture for Improving Urinary Incontinence After Radical Prostatectomy","Early Electroacupuncture for Urinary Continence After Radical Prostatectomy: A Randomized, Single-Blind, Sham-Electroacupuncture-Controlled, Parallel-Group, Multicenter Clinical Trial","EA","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years (inclusive) with a diagnosis of localized prostate cancer scheduled for radical prostatectomy.\n2. Clinical tumor stage ≤ cT2bN0M0 confirmed by preoperative evaluation.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Willingness to participate in the study and provision of written informed consent.\n\nExclusion Criteria:\n\n1. Presence of preoperative detrusor overactivity, urethral stricture, urge urinary incontinence, stress urinary incontinence, or overflow urinary incontinence.\n2. Preoperative International Prostate Symptom Score (IPSS) ≥ 20.\n3. Concurrent urogenital infectious diseases (e.g., acute urethritis, acute cystitis).\n4. History of pelvic radiotherapy.\n5. Previous prostate surgery.\n6. Severe cardiovascular disease, hepatic or renal dysfunction, or coagulation disorders.\n7. Presence of psychiatric or psychological conditions impairing the ability to provide coherent feedback.\n8. Receipt of any acupuncture treatment within one month prior to the study.\n9. Needle phobia, history of fainting during acupuncture, or strong aversion to acupuncture therapy.\n10. Any other condition considered by the investigators to render the patient unsuitable for study participation.",{"count":235,"type":21},216,[24],"This clinical trial aims to find out if early electroacupuncture (EA) helps people recover the ability to control urination and is safe after surgery to remove the prostate gland for prostate cancer (radical prostatectomy).\n\nParticipants are people aged 18 to 80 with localized prostate cancer who have had radical prostatectomy and are in good physical condition (ECOG score 0-1, meaning they can manage daily activities well).\n\nIt will answer two key questions:\n\nDoes early EA make more people fully control their urination 3 months after prostate surgery? How does early EA affect urination control and safety at 1, 6, and 12 months after surgery? Researchers will compare two groups: one getting EA and the other getting a fake version (sham EA ) to see if EA works better.\n\nParticipants will start treatment 1 week after surgery, getting EA or sham EA 3 times a week for 6 weeks, 20 minutes each time. They will also complete tests to check urination control and fill out surveys about their urination, quality of life, and symptoms at different times. Their safety will be watched closely too.",[214],[240,214,241,242],"Electroacupuncture","Radical Prostatectomy","Urinary Continence Recovery","2025-11-17",{"date":245,"type":34},"2025-11-24",{"date":247,"type":21},"2025-11-25",{"date":249,"type":21},"2029-02-25",{"name":40,"class":41},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":208,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":4},"100608199","phase-2-efficacy-of-gemcitabine-submucosal-injection-for-preventing-recurrence-in-intermediate--and-high-risk-non-muscle-invasive-bladder-cancer-a-randomized-trial-100608199","NCT07198451","Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial","Efficacy Evaluation of Submucosal Injection of Gemcitabine in Preventing Recurrence of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized, Single-Blind, Multicenter Clinical Study","GEM-IR-NMIBC","Inclusion Criteria:\n\n1. Patients aged 18 to 80 years (inclusive) with radiologically confirmed bladder tumor and scheduled to undergo transurethral resection of bladder tumor (TURBT).\n2. Postoperative pathological confirmation of intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC).\n3. Voluntarily participate in the study and sign the informed consent form, ensuring the patient fully understands the trial purpose, risks, and right to withdraw.\n\nExclusion Criteria:\n\n1. Preoperative comorbidities including detrusor overactivity, urethral stricture, urge incontinence, stress incontinence, or overflow incontinence.\n2. Concurrent urogenital infectious diseases (e.g., acute urethritis, acute cystitis).\n3. History of pelvic radiotherapy.\n4. Receiving systemic anti-tumor therapy for any malignant tumor.\n5. Severe cardiovascular disease, hepatic or renal insufficiency, or coagulation dysfunction.\n6. Presence of mental illness or psychological disorders that impair normal communication.\n7. Any other situation deemed by the investigator as unsuitable for participation in this clinical study.",{"count":260,"type":21},320,[157,158],"Bladder cancer is the most common malignant tumor of the urinary system in China, and its incidence has been increasing year by year. It is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). NMIBC accounts for 75% of newly diagnosed bladder cancer cases, and transurethral resection of bladder tumor (TURBT) followed by postoperative intravesical therapy is the standard treatment for NMIBC. However, the 5-year recurrence rate of NMIBC remains as high as 50%, with 20-30% of patients progressing to MIBC. MIBC is characterized by rapid progression and a high tendency for metastasis. The 5-year survival rate for patients with metastatic bladder cancer is only 5.4%. This study aims to investigate the efficacy of submucosal injection of the chemotherapeutic agent gemcitabine in preventing recurrence of intermediate- and high-risk NMIBC. Additionally, it seeks to develop software and devices related to submucosal injection to promote the clinical application of this new approach in the chemotherapeutic management of NMIBC. This research is expected to bring a revolutionary breakthrough in the standardisation of whole-process diagnosis and treatment of NMIBC, holding significant scientific value and major clinical translational importance for improving therapeutic outcomes and prognosis of bladder cancer.",[264],"Non Muscle Invasive Bladder Cancer",[266,267,268,269,270],"non muscle invasive bladder cancer","Gemcitabine","Submucosal Injection","Recurrence","Randomized Controlled Trial","2025-09-22",{"date":273,"type":34},"2025-09-30",{"date":275,"type":21},"2025-10",{"date":277,"type":21},"2028-06",{"name":40,"class":41},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":286,"enrollmentInfo":287,"targetDuration":289,"studyType":290,"phases":4,"briefSummary":291,"conditions":292,"keywords":294,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":308},"100569158","eocrcpred-an-ai-model-to-predict-survival-in-eocrc-patients-after-surgery-100569158","NCT06690606","EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery","EOCRCPred: an AI Model for Predicting Overall Survival in Early-Onset Stage I-III Colorectal Cancer Patients Post-Radical Resection-A SEER Database and Dual-Center Chinese Medical Institutions Study","Inclusion Criteria:\n\n* Primary EOCRC confirmed by pathological histological examination (ICD-10 codes: C18.0, C18.2-18.9, C19.9, C20.9)\n* Radical surgery performed (Specific Surgery Codes 30-70, including partial\u002Fsubtotal colectomy, hemicolectomy, right\u002Fleft colectomy, and total colectomy, as well as partial or total removal of other organs and regional lymph nodes)\n* Stage I-III disease according to the 7th AJCC-TNM system\n\nExclusion Criteria:\n\n* Patients with multiple primary cancers or other malignancies\n* Survival time of less than 1 month, or absence of postoperative follow-up information\n* Incomplete critical clinical feature information","49 Years",{"count":288,"type":21},250,"1 Month","OBSERVATIONAL","The goal of this observational study is to develop a predictive model for overall survival in patients under the age of 50 who have undergone surgery for early-onset colorectal cancer (EOCRC). The main question it aims to answer is:\n\nCan machine learning models accurately predict the long-term survival of EOCRC patients after surgical treatment?\n\nParticipants who have already undergone surgery for EOCRC as part of their regular medical care will have their clinical data analyzed, with survival outcomes tracked through follow-up assessments. An online survival calculator will also be developed to aid clinicians and patients in predicting personalized survival outcomes.",[293],"Colorectal Cancer",[295,296,297,298,299],"AI model","prediction","Early-Onset Colorectal Cancer (EOCRC)","postoperative survival","surgery","2024-11-13",{"date":302,"type":34},"2024-11-15",{"date":304,"type":21},"2024-11-12",{"date":306,"type":21},"2025-05-11",{"name":40,"class":41},2,{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":153,"sex":16,"minAge":316,"maxAge":179,"enrollmentInfo":317,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":308},"100477408","the-association-of-transgelin-2-metallothionein-2-and-ezrin-with-asthma-100477408","NCT05496582","The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma","The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma: A Case-control Study","Inclusion Criteria:\n\n1. Males or females, aged 14-75 years;\n2. Patients with a definite diagnosis of bronchial asthma;\n3. The diagnosis of asthma according to the Global Initiative for Asthma (GINA), with positive bronchodilator responsiveness (reversibility) test;\n4. Healthy volunteers without respiratory symptoms such as cough, wheezing, chest tightness or dyspnea;\n5. Agree with all procedures in this trial by signing a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients with chronic obstructive pulmonary disease or other airway disease;\n2. Complicated with other severe primary diseases (including hypertension, cancer, hyperthyroidism, bronchiectasia, cardiac insufficiency) and conditions that would prevent participation in the trial or put the participant at risk;\n3. Women who are known to be pregnant or breastfeeding;\n4. Not willing to participate;\n5. Psychiatric history and neurological disorders can not work normally;\n6. Other conditions that the researcher considers inappropriate to participate in this study.","14 Years",{"count":318,"type":21},100,"Asthma is one of the most common chronic respiratory diseases. Previous study found a series of differentially expressed genes and proteins (transgelin-2, metallothionein-2, ezrin) in asthmatic rat. The aim of the study is to investigate the changes and associations of these gene with asthma in human.",[29],"2024-05-06",{"date":323,"type":34},"2024-05-08",{"date":325,"type":34},"2022-11-01",{"date":327,"type":21},"2026-12",{"name":40,"class":41},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":290,"phases":4,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100282552","multicenter-cohort-study-on-osteoporosis-100282552","NCT02958020","Multicenter Cohort Study on Osteoporosis","Multicenter Cohort Study on Osteoporosis in the Middle-aged and Elderly People in Shanghai, China","Inclusion Criteria:\n\n* permanent residents\n* women aged from 45 to 79, and men aged from 50 to 79\n\nExclusion Criteria:\n\n* severe mental diseases, physical diseases or acute infectious diseases who could not cooperate with the survey.\n* lactating or pregnant women.","45 Years","79 Years",{"count":339,"type":21},50000,"This is a multicenter cohort study on osteoporosis in nine cities of China which locate in the east, south, north, west, middle of China. At least 3000 middle-aged and elderly permanent residents (women aged from 45 to 79, and men aged from 50 to 79) in every city will be enrolled. Residents with severe mental diseases, physical diseases or acute infectious diseases who could not cooperate with the survey as well as lactating or pregnant women were excluded. All the enrolled residents who signed informed consent will finish questionnaire including demographic characteristics, history of smoking, alcohol drinking, falls and fracture, family genetic history, chronic diseases and medicine,diary and physical practice，stool and urine status. Osteoporosis risk, health status, constitution of traditional Chinese medicine (TCM),symptoms of kidney yang deficiency in TCM，living environment,sweating status will be evaluated. Fasting blood glucose test and other blood tests for liver and kidney function,bone metabolism，vitamins，vitamin D metabolism and transportation as well as calcium and phosphate metabolism, will be performed. Bone mineral density and physical examinations (height, weight, waist circumference, hip circumference,grip,sit-to-stand test, tongue coating and pulse) will also be performed at enrollment and every two years after enrollment. DNA of blood cells will be preserved for specific study such as SNP analyses.Tongue coating and feces will be preserved for microflora analyses.",[342],"Osteoporosis",[344],"cohort, osteoporosis, bone mineral density, Chinese","2021-09-21",{"date":347,"type":34},"2021-09-23",{"date":349,"type":34},"2016-11",{"date":351,"type":21},"2028-10",{"name":40,"class":41},12,""]